Pharmacy Medical News about rosiglitazone/metformin tablet

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
Diabetes, Obesity and Metabolism, 08/28/09

Raskin P et al. – The repaglinide/metformin FDC BID regimen showed efficacy that was non–inferior to that of the rosiglitazone/metformin FDC BID regimen currently in clinical use and a more rapid reduction of HbA1c values. Thus, repaglinide/metformin FDC BID is a clinically feasible alternative to rosiglitazone/metformin FDC BID.

<< Previous
NOP Receptor Activation Attenuates Antinociception Induced by...

Next >>
Functional characterization of human cytochrome p450 2s1 using a...

Therapeutic Drug Monitoring of Lopinavir in Human Immunodeficiency Virus-Infected Children Receiving Adult Tablets: Therapeutic Drug Monitoring of Lopinavir Tablets Given To Children
The Pediatric Infectious Disease Journal, 10/29/09 Relevance Score: 45%

Preparation of medicinal carbon tablets by modified wet compression method
Drug Development and Industrial Pharmacy, 10/29/09 Relevance Score: 42%

Cephalon Notified of Generic Filing for Armodafinil Tablets
Cephalon, 10/22/09 Relevance Score: 42%

Boehringer Ingelheim receives approval from the European Commission for Mirapexin/Sifrol prolonged-release, once daily tablet for the treatment of Parkinson`s disease
Boehringer Ingelheim, 10/15/09 Relevance Score: 42%

Mylan Announces Settlement Agreement Related to Vfend First-to-File Opportunity
Mylan, 10/15/09 Relevance Score: 42%